-
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
28 Apr 2025 12:28 GMT
… potential biomarkers for NT219 treatment.
Immunosuppressive mechanisms such … conference. About Purple Biotech
Purple Biotech Ltd. (NASDAQ… in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
AACR: Topical treatment offers relief from painful skin rash caused by targeted cancer therapy
28 Apr 2025 00:11 GMT
… while taking cetuximab or panitumumab, two common anti-EGFR treatments.
The … using gel with no active drug.
IMPACT
Researchers have shown … Medicine and Stem Cell Research at UCLA.
SESSION
The trial … presentation in a Clinical Trials Plenary Session at the …
-
Topical Treatment Provides Relief from Painful Skin Rash Induced by Targeted Cancer Therapy
27 Apr 2025 23:48 GMT
… research institutions and biotech innovation. Lutris Pharma … bench research, clinical trials, and eventual therapeutic … cetuximab, panitumumab Tags: acneiform rash managementanti-EGFR treatment … cancer treatment solutionsLUT014 clinical trial findingsmanaging …
-
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
30 Apr 2025 06:00 GMT
… biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment … States Food and Drug Administration granted regulatory … or without cetuximab, for the treatment of patients … of NBTXR3 with Janssen Pharmaceutica NV, a Johnson …
-
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
30 Apr 2025 06:00 GMT
… « Société »), société de biotechnologie en phase clinique avancée, pionnière … la Food and Drug Administration des États-Unis … , avec ou sans cetuximab, pour le traitement … Pharmaceutica NV. À propos de NANOBIOTIX Nanobiotix est une société de biotechnologie …
-
SUNLIGHT Trial Defines CRC in the Refractory Setting
24 Apr 2025 16:50 GMT
… in the Department of Medical Oncology and Therapeutics Research … treatment options based on findings from the SUNLIGHT trial … combination with cetuximab [Erbitux]—that are FDA approved.6
What … the lookout for clinical trials to improve outcomes.
REFERENCES …
-
Merck KGaA to Acquire SpringWorks for $3.9B, Expanding Rare Cancer Footprint
29 Apr 2025 20:00 GMT
… who require systemic treatment, approved by the FDA in 2023.
… , co-head of European Pharmaceuticals & Life Science equity … came from a single drug, Erbitux® (cetuximab), which is indicated … managing director and senior biotechnology analyst with TD Cowen. …
-
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
29 Apr 2025 20:05 GMT
… and RAS mutations
Preferential drug distribution into tumor tissues
… plus anti-PD-1 or cetuximab in KRAS mutant models
… 47;MAPK pathway for the treatment of patients with cancer. We … , and completion of clinical trials and preclinical studies; our dependence …
-
Topical Gel Significantly Soothes Painful Skin Rash Caused by Anti-EGFR Therapies for Colorectal Cancer
28 Apr 2025 21:34 GMT
… clinical trial, which the investigators say confirm the treatment’s … and treatment outcomes.”
Anti-EGFR therapies, such as cetuximab and … 118 patients across 23 medical centers. Patients had colorectal … gel with no active drug.
According to the scientists …
-
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
28 Apr 2025 05:44 GMT
… anti-EGFR therapies, such as cetuximab and panitumumab. However, EGFR … treatments.
The trial enrolled 118 patients with colorectal cancer across 23 medical … fees from Asymmetric Therapeutics, Deciphera Pharmaceuticals, Erasca, Janssen Scientific Affairs, …
About
© 1995-2025